Generating destination analysis
Catalyst Play
Featured in “Three Gene-Editing Stocks to Own Before Biotech's Fall 2026 Catalyst Wave”
Beam Therapeutics pioneered base editing — rewriting DNA without cutting it, with far fewer off-target effects. With hematology front and center at ASH and its lead programs advancing, Beam is the highest-leverage way to own the next generation of genetic medicine.
The catalyst: The back half of 2026 is one of the most catalyst-dense stretches biotech has seen in years. The ESMO oncology congress and the ASH hematology meeting both land in the autumn, and the FDA's decision calendar is stacked — including a closely watched November 14 PDUFA date for ivonescimab in lung cancer. Clusters like this drive sector-wide risk-on, and capital flows first to the platforms with the deepest pipelines and clearest readouts. These three sit at the center of genetic medicine.
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Beam Therapeutics
Beam Therapeutics is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Base editing platform with differentiated gene-editing pipeline. With a $3B market capitalization and no current profitability, Beam Therapeutics has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Unlock Full BEAM Analysis
Expert analysis and coverage for Beam Therapeutics
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Regeneron Pharmaceuticals
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.